Long after Merck and Bristol Myers created a multibillion-dollar market, the PD-1 leaders are once again duking it out — this time over a $12B-plus pot
Six years after Merck and Bristol Myers Squibb captured the attention of the oncology world with the first approval of their PD-1 drugs Keytruda and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
